Caris Life Sciences has integrated a platinum resistance AI signature into its Caris AI Insights portfolio. This tool predicts early resistance to first-line platinum-based chemotherapy in high-grade serous ovarian cancer patients by assessing molecular features that indicate progression or recurrence within six months.

The signature leverages Caris’ CodeAI platform, processing whole exome sequencing, whole transcriptome sequencing and clinical data from its real-world database. By combining multimodal datasets, the AI model generates a risk score and classifies patients as platinum sensitive or resistant, supplemented by Kaplan-Meier curves for contextual risk assessment.

Clinicians can request the platinum resistance signature through the Caris Molecular Tumor Board Report when ordering the MI Cancer Seek tissue-based assay. Availability of this insight enables personalized treatment planning, particularly in light of FDA approval for new combination therapies targeting platinum-resistant ovarian cancer.